Plasma Cell Disorder Clinical Trial
Official title:
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are: - genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing - genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients. - disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS. - correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients. The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05032339 -
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
|
||
| Active, not recruiting |
NCT03480360 -
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
|
Phase 3 | |
| Recruiting |
NCT04879043 -
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT02274519 -
Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma
|
N/A | |
| Not yet recruiting |
NCT06313502 -
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
|
Phase 1 | |
| Active, not recruiting |
NCT02041325 -
Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias
|
Phase 2 |